Arrowhead Pharmaceuticals (ARWR) Long-Term Deferred Tax (2012 - 2013)
Arrowhead Pharmaceuticals (ARWR) posted Long-Term Deferred Tax of $40.2 million for Q3 2013, down 1.71% on a QoQ basis from $40.9 million in Q3 2012, and down 1.71% year-over-year from $40.9 million in Q3 2012.
Arrowhead Pharmaceuticals (ARWR) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Arrowhead Pharmaceuticals' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $40.2 million for Q3 2013.
- Quarterly Long-Term Deferred Tax fell 1.71% year-over-year to $40.2 million in Q3 2013, while the trailing twelve-month figure through Sep 2013 was $40.2 million (down 1.71% YoY) and the FY2013 annual result came in at $40.2 million, down 1.71% from the prior year.
- Long-Term Deferred Tax was $40.2 million for Q3 2013 at Arrowhead Pharmaceuticals, down from $40.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $40.9 million in Q3 2012 and bottomed at $40.2 million in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 40.20 Mn |
| Sep 30, 2012 | 40.90 Mn |